Request Trial
Sean Pavone / Shutterstock.com
16 January 2026NewsCareersMarisa Woutersen

Senior four-partner team leaves A&O Shearman

The team, known for pharmaceutical and biotechnology patent litigation—including Hatch-Waxman and BPCIA disputes—as well as trade secret and licensing matters, joins a rival US firm.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Careers
Irish law firms announce merger
10 November 2026   Leading IP practices join forces to build a national powerhouse in Dublin and Cork, offering combined expertise in life sciences, medical technology, engineering, software, electronics, communications, and advanced manufacturing.
Careers
Dykema’s new trademark pro will be a ‘tremendous asset’ to clients
4 November 2026   Joining in Wisconsin, the senior counsel brings “sophisticated” trademark experience and leadership, and counts biotechnology among her sectors.
Careers
Fenwick hires NY partner to advise on regulatory matters
2 November 2026   New partner joins from Goodwin, where he was a life sciences partner, bringing experience in healthcare transactions, and regulatory and strategic counselling, among other areas.


Editor's picks

In-house counsel rethink patent filing strategies as costs mount
In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026

Editor's picks

In-house counsel
In-house counsel rethink patent filing strategies as costs mount
3 November 2026
Pharma
Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility
20 October 2026
MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026
Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026
In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026

More features

‘No medicine is off limits’: US Chamber of Commerce says stricter import rules may deter fakes
GSK and Moderna settle cross-border patent dispute over vaccine tech
Eli Lilly follows Novo in UK High Court bid to block ‘black-market websites’
Irish law firms announce merger
How in-house teams can get more value from external counsel
Settled expectations, the six-year rule, and developments in USPTO policy
Regulatory and patent teams must align, say Amgen, Genentech, ORIC
EPO starts using AI for minutes but no access to transcripts for parties